#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Peritoneal neoplasm Mucous membrane pemphigoid Advanced systemic mastocytosis Hereditary neuropathic amyloidosis Hydrocephalus Ovarian epithelial cancer Meningococcal immunisation X-linked lymphoproliferative syndrome Progressive familial intrahepatic cholestasis Arginase deficiency Infection in an immunocompromised host Plasma cell myeloma recurrent Noonan syndrome Thymic carcinoma Synovitis More trials…

    Learn about Rare Diseases

    Rett syndrome – Life with Disease Angiosarcoma non-metastatic Chronic granulomatous disease – Treatment Paroxysmal nocturnal haemoglobinuria – Diagnostics Alveolar rhabdomyosarcoma – Life with Disease Hepatic angiosarcoma Mantle cell lymphoma stage IV – Diagnostics Glomerulonephritis membranoproliferative – Basic Information Pleomorphic leiomyosarcoma Isodicentric chromosome 15 syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Calcitriol AZD4512 Pelacarsen Vemircopan LUTETIUM LU-177 Ponesimod Pertechnetate (99Mtc) Sodium MARALIXIBAT Alisertib Sodium Sertindole Pioglitazone Arginine Hydrochloride Danazol NORGESTIMATE Cenobamate Nilutamide Betaxolol Mps-216 Buparlisib Abiraterone More therapies…

    Learn about Your Condition

    Breast cancer in situ Ovarian epithelial cancer Ureteric cancer Arterial tortuosity syndrome Pterygium Growth hormone deficiency Alveolar proteinosis Partial seizures Acute hepatic failure Anal abscess Basal cell naevus syndrome Pulmonary resection Progressive multiple sclerosis Splenic marginal zone lymphoma Affective disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Lisaftoclax
    • Azacitidine
    Belgium Bulgaria Czechia Finland France Germany +7

  • Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Study of ALE.P02 for Adults with Advanced or Metastatic Squamous Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • ALE.P02
    • Pembrolizumab
    France Italy Spain

  • Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Palbociclib
    • Inavolisib
    • Letrozole
    France Germany Italy Poland Spain

  • Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

    Recruiting

    3 1
    Investigated Drugs:
    • Elritercept
    Bulgaria Czechia France Germany Hungary Ireland +5

  • Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • NADOFARAGENE FIRADENOVEC
    Czechia Denmark France Italy Poland Spain

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer recurrent
    • Ovarian cancer recurrent
    Investigated Drugs:
    • H2-Receptor Antagonists
    • Bevacizumab
    • Buclizine Hydrochloride
    Austria Belgium Czechia Denmark Finland France +8

  • Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

    Recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    • Temozolomide
    Czechia France Germany Italy Poland Spain

  • Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Amivantamab
    • Bevacizumab
    • Cetuximab
    Belgium France Germany Hungary Italy The Netherlands +4

  • Study on Luspatercept for Treating Anemia in Patients with Myelodysplastic Syndromes (MDS) with del5q, Resistant to Prior Treatments and Needing Blood Transfusions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Luspatercept
    Italy
Previous Page
1 … 15 16 17 18 19 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!